The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03778320




Registration number
NCT03778320
Ethics application status
Date submitted
13/12/2018
Date registered
18/12/2018
Date last updated
15/03/2019

Titles & IDs
Public title
A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers
Scientific title
A Randomized Single Dose Crossover Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of CTP-692 Versus D-Serine
Secondary ID [1] 0 0
CP692.1001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CTP-692
Treatment: Drugs - D-Serine

Experimental: CTP-692 -

Active Comparator: D-Serine -


Treatment: Drugs: CTP-692
Single oral dose

Treatment: Drugs: D-Serine
Single oral dose

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The number of AEs in participants as a measure of safety and tolerability.
Timepoint [1] 0 0
7 days
Primary outcome [2] 0 0
Measurement of CTP-692 exposure in plasma
Timepoint [2] 0 0
48 hours

Eligibility
Key inclusion criteria
- Must give written and informed consent and any authorizations required by local law.

- Must have a body mass index (BMI) between 18 kg/m2 and 32 kg/m2, inclusive
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Screening laboratory measurements outside the normal range associated with potential
risk for the treatment under investigation at screening and/or prior to the first dose
of study drug

- Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
virus surface antigen or hepatitis C virus antibody

- History of clinically significant central nervous system (e.g., seizures), cardiac,
pulmonary, metabolic, renal, hepatic or gastrointestinal (GI) conditions

- Positive drug or alcohol test at screening or prior to the first dose of study drug

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Concert Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will assess the safety, tolerability and pharmacokinetic (PK) profile of CTP-692
vs D serine.
Trial website
https://clinicaltrials.gov/show/NCT03778320
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Emily McIntyre
Address 0 0
Concert Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications